Impact of race and ethnicity on features and outcome of ductal carcinoma in situ of the breast
- PMID: 22736444
- PMCID: PMC3461121
- DOI: 10.1002/cncr.27707
Impact of race and ethnicity on features and outcome of ductal carcinoma in situ of the breast
Abstract
Background: The impact of race and ethnicity on the biologic features and outcome variables of women who are diagnosed with preinvasive breast cancer-ductal carcinoma in situ (DCIS)-has not been addressed widely in the published literature.
Methods: Patient demographic, clinical, and pathologic features and outcome variables were analyzed with respect to the patient's initial self-reported race/ethnicity among women who received treatment for a diagnosis of pure DCIS from 1996 to 2009.
Results: Of 1902 patients, 1411 were white (74.2%), 214 were African American (11.3%), 175 were Hispanic (9.1%), and 102 were Asian/Pacific Islander (5.4%). The majority of patients were between ages 41 and 70 years (83%). Patients of Hispanic and Asian/Pacific Islander descent were significantly younger than white and African American patients (P < .001). DCIS size and grade, the presence of necrosis, and the frequency of breast-conserving surgery did not differ significantly between groups. African American patients aged >70 years and Hispanic patients aged <50 years were significantly more likely to have estrogen receptor-positive DCIS than patients of other races in the same age categories (P < .001). Adjuvant radiotherapy and tamoxifen were received significantly less often by white women (P < .001). At a median follow-up of 4.8 years (range, 1-14 years), recurrence rates and the development of contralateral breast cancer did not differ significantly among racial/ethnic groups when stratified by treatments received.
Conclusions: There was variation in age at presentation, biologic features, and treatment of DCIS among the different ethnic groups. Additional studies with larger numbers of ethnic minority patients are needed to confirm whether the consistent application of evidence-based treatment practices presents an opportunity for reducing disparities in patients with DCIS.
Copyright © 2012 American Cancer Society.
Similar articles
-
Receipt of mastectomy and adjuvant radiotherapy following breast conserving surgery (BCS) in New Zealand women with BCS-eligible breast cancer, 2010-2015: an observational study focusing on ethnic differences.BMC Cancer. 2023 Aug 17;23(1):766. doi: 10.1186/s12885-023-11248-9. BMC Cancer. 2023. PMID: 37592208 Free PMC article.
-
Recent trends and racial/ethnic differences in the incidence and treatment of ductal carcinoma in situ of the breast in California women.Cancer. 2003 Feb 15;97(4):1099-106. doi: 10.1002/cncr.11104. Cancer. 2003. PMID: 12569612
-
Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.JAMA Oncol. 2015 Oct;1(7):888-96. doi: 10.1001/jamaoncol.2015.2510. JAMA Oncol. 2015. PMID: 26291673
-
The impact of surgery on ductal carcinoma in situ outcomes: the use of mastectomy.J Natl Cancer Inst Monogr. 2010;2010(41):197-9. doi: 10.1093/jncimonographs/lgq032. J Natl Cancer Inst Monogr. 2010. PMID: 20956829 Free PMC article. Review.
-
Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy.Breast Cancer Res Treat. 2021 Apr;186(3):617-624. doi: 10.1007/s10549-021-06129-3. Epub 2021 Mar 6. Breast Cancer Res Treat. 2021. PMID: 33675490 Free PMC article. Review.
Cited by
-
Racial disparities in risk of second breast tumors after ductal carcinoma in situ.Breast Cancer Res Treat. 2014 Nov;148(1):163-73. doi: 10.1007/s10549-014-3151-z. Epub 2014 Sep 27. Breast Cancer Res Treat. 2014. PMID: 25261293 Free PMC article.
-
Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018.Breast Cancer Res Treat. 2024 Dec;208(3):577-587. doi: 10.1007/s10549-024-07453-0. Epub 2024 Aug 16. Breast Cancer Res Treat. 2024. PMID: 39148003
-
Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial.Ann Surg Oncol. 2023 Dec;30(13):8404-8411. doi: 10.1245/s10434-023-14344-z. Epub 2023 Sep 30. Ann Surg Oncol. 2023. PMID: 37777685 Clinical Trial.
-
Investigating the effectiveness of adjuvant therapy for patients with hormone receptor-positive ductal carcinoma in situ.PLoS One. 2022 Jan 28;17(1):e0262934. doi: 10.1371/journal.pone.0262934. eCollection 2022. PLoS One. 2022. PMID: 35089956 Free PMC article. Clinical Trial.
-
Long-term risk perceptions of women with ductal carcinoma in situ.Oncologist. 2013;18(4):362-8. doi: 10.1634/theoncologist.2012-0376. Epub 2013 Apr 8. Oncologist. 2013. PMID: 23568001 Free PMC article.
References
-
- Kuerer HM, Albarracin CT, Yang WT, et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009;27:279–288. - PubMed
-
- Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA. Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol. 2006;24:1342–1349. - PubMed
-
- Newman LA, Martin IK. Disparities in breast cancer. Curr Probl Cancer. 2007;31:134–156. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical